日本第二阶段对177Lu-PSMA-I&T的高级前列腺癌试验中注册的第一位患者。 First patient enrolled in Japan’s Phase 2 trial of 177Lu-PSMA-I&T for advanced prostate cancer.

类、PeptiDream和PDRadiopharma在日本对高级前列腺癌进行177Lu-PSMA-I&T测试的第二阶段试验中注册了第一个病人。 Curium Group, PeptiDream, and PDRadiopharma have enrolled the first patient in a Phase 2 trial in Japan testing 177Lu-PSMA-I&T for advanced prostate cancer. 该试验利用64Cu-PSMA-I&T进行诊断成像,评估该疗法在有抗转移性剖析前列腺癌的病人中的安全性和有效性。 The trial evaluates the therapy’s safety and effectiveness in patients with metastatic castration-resistant prostate cancer, using 64Cu-PSMA-I&T for diagnostic imaging. 这项研究以全球数据为基础,包括ECLIPSE第三阶段试验,目的是扩大日本获得精密放射药品治疗的机会。 The study builds on global data, including the ECLIPSE Phase 3 trial, and aims to expand access to precision radiopharmaceutical treatments in Japan.